PO-047 Etarget: a digital science solution to integrate clinical and genomic data for the manchester molecular tumour board (MTB)

Introduction null Manchester Cancer Research Centre (MCRC) has established an MTB to facilitate precision medicine decision-making within the TARGET trial (Tumour chAracterisation to Guide Experimental Targeted Therapy). The MTB meets monthly to review clinical data and next generation sequencing (NGS) results from tumour tissue and circulating DNA (ctDNA) for patients being considered for early phase clinical trials. Initially the MTB relied on...